Elutia reports third-quarter results and advances NXT-41x toward FDA filing
Elutia reported third-quarter 2026 results on November 5, alongside plans to submit its NXT-41x antibacterial surgical matrix to the FDA in Q4 2026. A GLP rabbit study found no viable bacteria after 8-log MRSA or 6-log E. coli challenges, while the company added $26 million without an equity offering. Cardiovascular revenue rose 20% year over year, and Elutia expects NXT-41x clearance in the first half of 2027 and a full commercial launch in 2028.
Why it matters
The FDA filing plan creates a regulatory milestone for Elutia's lead product, but clearance remains pending. Elutia expects the $26 million in added capital to fund operations through anticipated clearance and the first full year of NXT-41x commercialization in 2028.
Key facts
- 1Elutia plans to submit NXT-41x to the FDA in the fourth quarter of 2026. sec.gov
- 2The GLP rabbit study reported no viable bacteria after 8-log MRSA or 6-log E. coli challenges. sec.gov
- 3Elutia received $26 million without an equity offering. sec.gov
- 4Cardiovascular revenue increased 20% year over year in the third quarter of 2026 and 65% for the first nine months of 2026. sec.gov
- 5Elutia reported $1.1 million in third-quarter revenue, an adjusted gross margin of 85%, and a $6.5 million net loss. investing.com
- 6Elutia anticipates NXT-41x clearance in the first half of 2027 and a full commercial launch in 2028. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.